VeedAtlas Research Desk
Global cannabis market updates connected to the brands, products, regulators, and countries people search for.
Aurora's board unanimously rejected Curaleaf's unsolicited bid, triggering a public dispute over financial projections, shareholder control, and legal compliance.
Read the evidence-backed report →The Canadian producer says Curaleaf’s bid undervalues its assets and would shift risk onto Aurora shareholders.
Read the evidence-backed report →The acquisition makes Cresco the top medical marijuana retailer and wholesaler in Pennsylvania, the second-largest U.S. medical cannabis market.
Read the evidence-backed report →An op-ed argues that the April federal rescheduling order is accelerating a quiet wave of cannabis consolidation, with pharma and agricultural companies positioning for first-mover advantages.
Read the evidence-backed report →The Canadian producer acquires Internod Pharma and HAP Pharma to secure direct import, distribution, and pharmacy capabilities in the UK medical cannabis market.
Read the evidence-backed report →Curaleaf has formally launched its unsolicited bid for Aurora Cannabis, setting a December 1 deadline while Aurora urges shareholders to take no action.
Read the evidence-backed report →A US$236 million hostile offer would combine two of the continent's largest medical cannabis operators, but Aurora's board is not yet convinced.
Read the evidence-backed report →The deal will rebrand eight Ponderosa Dispensary locations under JARS Cannabis and form a 27-store network across Arizona.
Read the evidence-backed report →The Canadian producer disputes the U.S. operator's public statements about a takeover approach and urges investors not to act prematurely.
Read the evidence-backed report →